PL1920781T3 - Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów - Google Patents

Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów

Info

Publication number
PL1920781T3
PL1920781T3 PL06090208T PL06090208T PL1920781T3 PL 1920781 T3 PL1920781 T3 PL 1920781T3 PL 06090208 T PL06090208 T PL 06090208T PL 06090208 T PL06090208 T PL 06090208T PL 1920781 T3 PL1920781 T3 PL 1920781T3
Authority
PL
Poland
Prior art keywords
prophylaxis
tumors
compositions
core
treatment
Prior art date
Application number
PL06090208T
Other languages
English (en)
Inventor
Steffen Goletz
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39200183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1920781(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of PL1920781T3 publication Critical patent/PL1920781T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PL06090208T 2006-11-10 2006-11-10 Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów PL1920781T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090209A EP1920782A1 (en) 2006-11-10 2006-11-10 Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP06090208.7A EP1920781B1 (en) 2006-11-10 2006-11-10 Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors

Publications (1)

Publication Number Publication Date
PL1920781T3 true PL1920781T3 (pl) 2015-06-30

Family

ID=39200183

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06090208T PL1920781T3 (pl) 2006-11-10 2006-11-10 Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów

Country Status (17)

Country Link
US (2) US8592165B2 (pl)
EP (4) EP1920782A1 (pl)
JP (4) JP5771355B2 (pl)
KR (2) KR20090080554A (pl)
CN (1) CN101573138B (pl)
AU (2) AU2007316819B2 (pl)
BR (2) BRPI0718796A2 (pl)
CA (2) CA2668704A1 (pl)
EA (1) EA025395B1 (pl)
ES (1) ES2715045T3 (pl)
IL (2) IL198567A0 (pl)
MX (1) MX2009005004A (pl)
NO (1) NO20091748L (pl)
NZ (1) NZ577559A (pl)
PL (1) PL1920781T3 (pl)
RU (1) RU2460074C2 (pl)
WO (2) WO2008055702A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150126730A (ko) 2006-09-10 2015-11-12 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
US8741365B2 (en) 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
EP2459752A4 (en) * 2009-07-27 2013-01-23 Univ North Carolina ENTEROCOCCUS AND DEPOSIT BACTEROIDS FOR QUICK WATER QUALITY ASSESSMENT
GB2475226A (en) 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
AU2011261528A1 (en) * 2010-06-01 2013-01-10 Moore Research Enterprises Llc Cellular constituents from Bacteroides, compositions thereof, and therapeutic methods employing Bacteroides or cellular constituents thereof
AU2011313763A1 (en) * 2010-10-04 2013-05-30 Emma Allen-Vercoe Detection of Fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
CA2844543A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
CA2844542A1 (en) * 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms of the species bacteroides xylanisolvens
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
PL2877590T3 (pl) * 2012-06-26 2016-11-30 Sposób diagnozowania in vitro inwazyjnego zakażenia grzybiczego metodą spektrometrii masowej maldi-tof
CN102813916B (zh) * 2012-09-05 2015-03-11 北京希普生国际生物医学研究院 一种快速获取树突状细胞疫苗的制备方法及其应用
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP2818056A1 (en) * 2013-06-25 2014-12-31 Biosearch S.A. Probiotic bacteria comprising metals, metal nanoparticles and uses thereof
CN113717964A (zh) * 2013-08-06 2021-11-30 达特茅斯学院理事会 非糖基化溶葡球菌素变体蛋白
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN104546933A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546932A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
KR102523805B1 (ko) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 면역 조정
KR20170091157A (ko) * 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
EP4548978A3 (en) 2015-01-29 2025-08-06 Oxyrase, Inc. Methods for inhibiting tumor growth
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RS59038B1 (sr) 2015-06-15 2019-08-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6426264B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3240554T3 (pl) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
HK1246670B (en) 2016-03-04 2020-05-15 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
EP3478093A4 (en) 2016-07-01 2020-03-04 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
EP3630136B1 (en) 2017-05-22 2021-04-21 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
EP3600363B1 (en) 2017-06-14 2020-12-02 4D Pharma Research Limited Compositions comprising bacterial strains
HUE052258T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
BR112019028301A2 (pt) 2017-07-05 2020-07-14 Evelo Biosciences, Inc. composições e métodos para tratar câncer com o uso de bifidobacterium animalis ssp. lactis
US20210396759A1 (en) * 2018-05-11 2021-12-23 Obi Pharma, Inc. Method for Predicting Human Immune Response
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
EP3870691A4 (en) 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
US20220257726A1 (en) * 2019-07-18 2022-08-18 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
KR20220137045A (ko) * 2020-02-03 2022-10-11 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 미생물을 단리하는 방법
CN115992084A (zh) * 2022-08-18 2023-04-21 吉林农业大学 表达牛巨噬细胞粒细胞集落刺激因子的重组乳酸菌及应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4672316A (en) 1983-08-19 1987-06-09 Werkzeugmaschinenfabrik Oerlikon-Buhrle Ag Method for calibrating a muzzle velocity measuring device
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
CA1333564C (en) 1988-08-02 1994-12-20 Thomas Julius Borody Treatment of gastro-intestinal disorders
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
DK0573551T3 (da) 1991-02-27 2003-08-04 Micromet Ag Serinrige peptidlinkere
CA2118010C (en) 1992-04-13 2003-10-28 Donald Kufe Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US7137011B1 (en) 1993-09-01 2006-11-14 Sandisk Corporation Removable mother/daughter peripheral card
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP2660175B2 (ja) * 1994-10-19 1997-10-08 北海道 キクイモ由来のレクチンおよびその分離精製法
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US5939404A (en) * 1995-12-27 1999-08-17 Ngk Insulators, Ltd. Cancer metastasis inhibitor containing a streptococcus agalactiae Ia type or Ib type surface polysaccharide as a main ingredient
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
JP2001523480A (ja) 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
PT1054693E (pt) * 1998-02-20 2009-01-22 Genentech Inc Inibidores da activação do complemento
JP2000028599A (ja) * 1998-04-15 2000-01-28 Ebara Corp Ｄ―マンノ―ス識別アフィニティ―担体とその使用方法
CA2363297C (en) 1999-03-02 2011-08-09 Michael J. Betenbaugh Engineering intracellular sialylation pathways
DK1167537T3 (da) 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
EP1419176A2 (en) 2001-08-17 2004-05-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
CN1201817C (zh) * 2001-11-09 2005-05-18 北京大学肝病研究所 一种治疗肝癌的肿瘤ct抗原免疫诱导剂及其制备方法
KR100506766B1 (ko) 2001-11-20 2005-08-05 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및이를 포함하는 융합단백질
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
ES2353753T3 (es) 2002-08-16 2011-03-04 Glycotope Gmbh Procedimiento para la producción de lisados de células tumorales inducidas por temperatura para usar como compuestos inmunógenos.
WO2004029621A2 (en) * 2002-09-26 2004-04-08 Novartis Ag Tcell mediator/modulator assay based upon tcell restricted transgenic mouse
DE10256900A1 (de) * 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
EP1604016B1 (en) * 2003-02-27 2009-01-14 NorthWest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
GB0315991D0 (en) * 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
AU2005215889B9 (en) 2004-02-13 2011-11-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
EP1778280A1 (en) * 2004-07-01 2007-05-02 Kobenhavns Universitet Method for multiple sclerosis treatment and prophylaxis by treatment of leptospira infection
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
AR054603A1 (es) * 2005-08-01 2007-06-27 Canada Natural Resources Semillas de canola amarillas que comprenden bajo contenido de aceite linolenico y alto contenido oleico y grano molido de bajo contenido de fibra
KR20150126730A (ko) * 2006-09-10 2015-11-12 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
US8741365B2 (en) * 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
CA2844543A1 (en) * 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen

Also Published As

Publication number Publication date
JP2015133979A (ja) 2015-07-27
EP2099480A2 (en) 2009-09-16
US20100158952A1 (en) 2010-06-24
RU2460074C2 (ru) 2012-08-27
JP2010508834A (ja) 2010-03-25
CA2668704A1 (en) 2008-05-15
JP2010508833A (ja) 2010-03-25
EP2101814A1 (en) 2009-09-23
WO2008055703A3 (en) 2008-12-04
AU2007316819B2 (en) 2013-08-22
KR20090080554A (ko) 2009-07-24
WO2008055703A2 (en) 2008-05-15
JP2015134813A (ja) 2015-07-27
BRPI0718796A2 (pt) 2014-02-18
CA2668603A1 (en) 2008-05-15
WO2008055702A1 (en) 2008-05-15
EP1920781B1 (en) 2015-03-04
CN101573138A (zh) 2009-11-04
CN101573138B (zh) 2015-04-29
IL198626A (en) 2015-05-31
NO20091748L (no) 2009-07-14
AU2007316820B2 (en) 2013-09-05
EA200970471A1 (ru) 2009-12-30
MX2009005004A (es) 2009-07-31
KR20150054014A (ko) 2015-05-19
NZ577559A (en) 2012-01-12
IL198626A0 (en) 2011-08-01
EP2099480B1 (en) 2019-01-09
AU2007316819A1 (en) 2008-05-15
BRPI0719005A2 (pt) 2013-12-17
EP2099480B2 (en) 2024-06-12
IL198567A0 (en) 2011-08-01
WO2008055703A9 (en) 2008-10-02
JP5771355B2 (ja) 2015-08-26
ES2715045T3 (es) 2019-05-31
EP1920782A1 (en) 2008-05-14
EA025395B1 (ru) 2016-12-30
AU2007316820A1 (en) 2008-05-15
US8592165B2 (en) 2013-11-26
EP1920781A1 (en) 2008-05-14
HK1136219A1 (en) 2010-06-25
US9494587B2 (en) 2016-11-15
US20100303837A1 (en) 2010-12-02
RU2009122204A (ru) 2010-12-20

Similar Documents

Publication Publication Date Title
PL1920781T3 (pl) Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
EP2137537B8 (en) Compositions and Uses for Treating Multiple Sclerosis
ZA200900388B (en) Compositions and methods for the treatment of mucositis
EP2007426A4 (en) COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
GB0909297D0 (en) Composition for the treatment of skin conditions
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0815632D0 (en) Compositions and methods for promoting the healing of tissue of multicellular organisms
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
EP1933853A4 (en) TREATMENT OF TISSUE DISTRACTION AND COMPOSITION FOR APPLYING THEREOF
PT1920781E (pt) Composições que compreendem um microrganismo core-1 positivo e sua utilização para o tratamento ou profilaxia de tumores
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0526292D0 (en) A composition for use in the treatment of a surface
GB0602857D0 (en) The treatment of sialorrhoea
AU2005904807A0 (en) Methods and compositions for the prophylaxis or treatment of cancers of the skin
GB0614097D0 (en) Medical treatments and compounds and compositions for use therein
GB0614095D0 (en) Medical treatments and compounds and compositions for use therein
HK1126674A (en) Uses and compositions for treatment of psoriatic arthritis
AU2006902176A0 (en) Water Treatment Composition